• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Diagnosis

Receiving a diagnosis of ALS/MND is a life-changing moment. This page explains what the diagnostic process typically involves and what people can expect in terms of how the disease progresses. It is intended as a general introduction. A neurologist or specialist will be the most important source of information for any individual situation.


How ALS/MND is diagnosed

There is no single test that confirms ALS/MND. Diagnosis is a process, and it can take time. A neurologist will typically conduct a series of assessments to identify signs of ALS/MND and to rule out other conditions that can cause similar symptoms.

The diagnostic process may include:

  • A detailed neurological examination to assess muscle strength, reflexes, coordination, and speech
  • Electromyography (EMG) and nerve conduction studies, which measure the electrical activity of muscles and nerves
  • MRI scans, to rule out other causes of symptoms such as spinal cord compression or stroke
  • Blood and urine tests, to exclude other conditions
  • In some cases, a muscle or nerve biopsy, or a lumbar puncture

Because ALS/MND shares some features with other neurological conditions, reaching a confirmed diagnosis can require multiple appointments and tests over a period of weeks or months. A second opinion from another specialist is a reasonable step, and many people find it helpful.

Once a diagnosis is confirmed, care is typically transferred to, or coordinated with, a multidisciplinary team. This team may include neurologists, physiotherapists, occupational therapists, speech therapists, respiratory specialists, dietitians, social workers, and others. For more on the care team and what it involves, see the Clinical Care section.


How ALS/MND progresses

ALS/MND affects each person differently. The rate and pattern of progression vary from one individual to the next, depending on factors such as which muscles are affected first, age at diagnosis, and overall health.

In most cases, ALS/MND begins with weakness or changes in one area — such as a hand, foot, or the muscles used for speaking or swallowing — and spreads over time to other parts of the body. The muscles that control breathing are typically affected as the disease progresses.

Cognitive and behavioural changes can also occur in some people living with ALS/MND, including difficulties with memory, language, or behaviour. These changes are more common in people who also have frontotemporal dementia (FTD), which overlaps with ALS/MND in a proportion of cases.

Because progression is variable, it is difficult to make precise predictions for any individual. A specialist or multidisciplinary care team is best placed to discuss what to expect based on a person’s specific situation.


Finding support after diagnosis

A diagnosis of ALS/MND affects not only the person diagnosed, but also family members and caregivers. Finding the right support early can make a significant difference.

The Alliance’s member associations provide support, information, and services to people living with ALS/MND and their families around the world. To find an association in your region, visit the Member Association directory.

Note: This page provides general information only. It is not a substitute for medical advice. Anyone with concerns about their symptoms or diagnosis should speak with a qualified healthcare professional.

Primary Sidebar

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Jon Newsome, USA

    Jon Newsome, USA

  • Liong Ting Ngu, Malaysia

    Liong Ting Ngu, Malaysia

  • Tso-Ta Huang, Taiwan

    Tso-Ta Huang, Taiwan

  • Dick Dayton, USA

    Dick Dayton, USA

  • Rosie Riley, USA

    Rosie Riley, USA

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Anderson Custodio Pinto, Brazil

    Anderson Custodio Pinto, Brazil

  • Juvenal Bayona Romero, Colombia

    Juvenal Bayona Romero, Colombia

  • Rudiger Hanemann, Germany

    Rudiger Hanemann, Germany

  • Shera Mukherjee, India

    Shera Mukherjee, India

  • Jason Goodman, USA

    Jason Goodman, USA

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • Purningam Jacob, India

    Purningam Jacob, India

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Armando González Gómez, Colombia

    Armando González Gómez, Colombia

  • Greg Heydet, USA

    Greg Heydet, USA

  • Den Haag, Netherlands

    Den Haag, Netherlands

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Len Johnrose, England

    Len Johnrose, England

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Mike Rannie, Canada

    Mike Rannie, Canada

  • Soledad Rodriguez, Spain

    Soledad Rodriguez, Spain

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Ali Var, Turkey

    Ali Var, Turkey

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Monica Soriano, Argentina

    Monica Soriano, Argentina

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • John Russo, USA

    John Russo, USA
    final3878

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Mike Cels, Canada

    Mike Cels, Canada

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Orlando Ruiz, Colombia

    Orlando Ruiz, Colombia

  • Denis Blais, Canada

    Denis Blais, Canada

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login